Congratulations To

Duality Biotherapeutics Inc (Stock Code: 9606.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets. 

(Source: www.hkex.com.hk)

CR SWCS Team is honoured to serve as DUALITY BIOTHERAPEUTICS, INC.’s Joint Company

Secretary, committed to ensuring governance, compliance, and sustained growth.